Effect of different molecular weight and terminal group PLGA on docetaxel nanoparticles: characterization and cytotoxic activity of castration-resistant prostate cancer cells

References

• Aheget H, Tristán-Manzano M, Mazini L, Cortijo-Gutierrez M, Galindo-Moreno P, Herrera C, Martin F, Marchal JA, Benabdellah K. 2020. Exosome: a new player in translational nanomedicine. J Clin Med. 26(9):2380.
   Google Scholar
• Arrieta O, Barrón F, Ramírez-Tirado LA, Zatarain-Barrón ZL, Cardona AF, Díaz-García D, Yamamoto-Ramos M, Mota-Vega B, Carmona A, Peralta-Álvarez MP, et al. 2020. Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non–small cell lung cancer: the PROLUNG phase 2 randomized clinical trial. JAMA Oncol. 6(6):856–864.
   PubMed Web of Science ®Google Scholar
• Baker JR. 2006. Nanotechnology for biology and medicine. Managing nano‐bio‐info‐cogno innovations. USA: Springer; p. 119–132.
   Google Scholar
• Barcia E, Boeva L, García-García L, Slowing K, Fernández-Carballido A, Casanova Y, Negro S. 2017. Nanotechnology-based drug delivery of ropinirole for Parkinson’s disease. Drug Deliv. 24(1):1112–1123.
   PubMed Web of Science ®Google Scholar
• Beneitez MC, Gil-Alegre ME. 2017. Critical quality attributes of control drug release systems and their impact on rational polymer selection. J Nanosci Nanotechnol. 17(6):3896–3902.
   Web of Science ®Google Scholar
• Bhattacharjee S. 2018. How efficient are the efficiency terms of encapsulation? Ther Deliv. 9(4):237–239.
   PubMed Web of Science ®Google Scholar
• Bissery MC. 1995. Preclinical pharmacology of docetaxel. Eur J Cancer. 31(4):1–6.
   Google Scholar
• Brigger I, Dubernet C, Couvreur P. 2002. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 54(5):631–651.
   PubMed Web of Science ®Google Scholar
• Budhian A, Siegel SJ, Winey KI. 2007. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm. 336(2):367–375.
   PubMed Web of Science ®Google Scholar
• Cao LB, Zeng S, Zhao W. 2016. Highly stable PEGylated poly (lactic-co-glycolic acid) (PLGA) nanoparticles for the effective delivery of docetaxel in prostate cancers. Nanoscale Res Lett. 11(1):305.
   PubMedGoogle Scholar
• Card JW, Magnuson BA. 2011. A review of the efficacy and safety of nanoparticle‐based oral insulin delivery systems. Am J Physiol Gastrointest Liver Physiol. 301(6):956–967.
   Web of Science ®Google Scholar
• Chang D, Lei J, Cui H, Lu N, Sun Y, Zhang X, Gao C, Zheng H, Yin Y. 2012. Disulfide cross-linked nanospheres from sodium alginate derivative for inflammatory bowel disease: Preparation, characterization, and in vitro drug release behavior. Carbohydr Polym. 88(2):663–669.
   Web of Science ®Google Scholar
• Chen Z, Tai Z, Gu F, Hu C, Zhu Q, Gao S. 2016. Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy. Eur J Pharm Biopharm. 107:130–141.
   PubMed Web of Science ®Google Scholar
• Crown J, O'Leary M, Ooi WS. 2004. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist. 9(S2):24–32.
   PubMedGoogle Scholar
• Di Cosimo S, Ferretti G, Fazio N, Silvestris N, Carlini P, Alimonti A, Gelibter A, Felici A, Papaldo P, Cognetti F. 2003. Docetaxel in advanced gastric cancer – a review of the main clinical trials. Acta Oncol. 42(7):693–700.
   PubMed Web of Science ®Google Scholar
• Esmaeili F, Dinarvand R, Ghahremani MH, Ostad SN, Esmaily H, Atyabi F. 2010. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles. Anticancer Drugs. 21(1):43–52.
   PubMed Web of Science ®Google Scholar
• Fraguas-Sánchez AI, Fernández-Carballido A, Simancas-Herbada R, Martin-Sabroso C, Torres-Suárez AI. 2020. CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer. Int J Pharm. 25(574):118916.
   Google Scholar
• Ganesh T. 2007. Improved biochemical strategies for targeted delivery of taxoids. Bioorg Med Chem. 15(11):3597–3623.
   PubMed Web of Science ®Google Scholar
• Griffiths JR. 1991. Are cancer cells acidic? Br J Cancer. 64(3):425–427.
   PubMed Web of Science ®Google Scholar
• Gyawali B, Koomulli-Parambil S, Iddawela M. 2016. Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer. Crit Rev Oncol Hematol. 102:118–124.
   PubMed Web of Science ®Google Scholar
• Haggag YA, Abu Ras B, El-Tanani Y, Tambuwala MM, McCarron P, Isreb M, El-Tanani M. 2020. Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells. Expert Opin Drug Deliv. 17(11):1655–1669.
   PubMed Web of Science ®Google Scholar
• Haggag YA, Yasser M, Tambuwala MM, El Tokhy SS, Isreb M, Donia AA. 2021. Repurposing of Guanabenz acetate by encapsulation into long-circulating nanopolymersomes for treatment of triple-negative breast cancer. Int J Pharm. 600(600):120532.
   PubMedGoogle Scholar
• Haggag YA, Yusuf A, Abosalha AKH, Tambuwala MM, Osman EY, El- Gizawy SA, Essa EA, Donia AA. 2021. Polymeric nanoencapsulation of zaleplon into PLGA nanoparticles for enhanced pharmacokinetics and pharmacological activity. Biopharm Drug Dispos. 42(1):12–23.
   PubMed Web of Science ®Google Scholar
• Hammadi NI, Abba Y, Hezmee MNM, Razak ISA, Jaji AZ, Isa T, Mahmood SK, Zakaria MZAB. 2017. Formulation of a sustained release docetaxel loaded cockle shell-derived calcium carbonate nanoparticles against breast cancer. Pharm Res. 34(6):1193–1203.
   PubMed Web of Science ®Google Scholar
• Hitt R, Rodriguez C. 2011. Docetaxel. In: Schwab M, editor. Encyclopedia of cancer. 3rd ed. Berlin (Germany): Springer-Verlag; p. 1148–1150.
   Google Scholar
• Hu CMJ, Aryal S, Zhang L. 2010. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv. 1(2):323–334.
   PubMedGoogle Scholar
• Kamali H, Khodaverdi E, Kaffash E, Sarem-Saffari A, Shiadeh SNR, Nokhodchi A, Hadizadeh F. 2021. Optimization and in vitro evaluation of injectable sustained-release of levothyroxine using PLGA-PEG-PLGA. J Pharm Innov. 16(4):688–698.
   Web of Science ®Google Scholar
• Kamba SA, Ismail M, Hussein-Al-Ali SH, Ibrahim TAT, Zakaria ZAB. 2013. in vitro delivery and controlled release of doxorubicin for targeting osteosarcoma bone cancer. Molecules. 18(9):10580–10598.
   PubMed Web of Science ®Google Scholar
• Katsumata N. 2003. Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer. 89(3):9–15.
   Google Scholar
• Kaur IP, Bhandari R, Bhandari S, Kakkar V. 2008. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 127(2):97–109.
   PubMed Web of Science ®Google Scholar
• Keum CG, Noh YW, Baek JS, Lim JH, Hwang CJ, Na YG, Shin SC, Cho CW. 2011. Practical preparation procedures for docetaxel-loaded nanoparticles using polylactic acid-co-glycolic acid. Int J Nanomed. 6:2225–2234.
   PubMed Web of Science ®Google Scholar
• Koopaei MN, Dinarvand R, Amini M, Rabbani H, Emami S, Ostad SN, Atyabi F. 2011. Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies. Int J Nanomed. 6:1903–1912.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Fenton C. 2005. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 65(17):2513–2531.
   PubMed Web of Science ®Google Scholar
• Magenheim B, Levy MY, Benita S. 1993. A new in vitro technique for evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure. Int J Pharm. 94(1-3):115–123.
   Google Scholar
• Makadia HK, Siegel SJ. 2011. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 3(3):1377–1397.
   PubMed Web of Science ®Google Scholar
• Manoochehri S, Darvishi B, Kamalinia G, Amini M, Fallah M, Ostad SN, Atyabi F, Dinarvand R. 2013. Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel. Daru. 21(1):58.
   PubMedGoogle Scholar
• Maor I, Asadi S, Korganbayev S, Dahis D, Shamay Y, Schena E, Azhari H, Saccomandi P, Weitz IS. 2021. Laser-induced thermal response and controlled release of copper oxide nanoparticles from multifunctional polymeric nanocarriers. Sci Technol Adv Mater. 22(1):218–233.
   PubMed Web of Science ®Google Scholar
• Marcianes P, Negro S, Barcia E, Montejo C, Fernández-Carballido A. 2019. Potential active targeting of gatifloxacin to macrophages by means of surface-modified PLGA microparticles destined to treat tuberculosis. AAPS PharmSciTech. 21(1):15.
   PubMed Web of Science ®Google Scholar
• Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. 2013. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev. 65(13-14):1866–1879.
   PubMed Web of Science ®Google Scholar
• Martín-Banderas L, Alvarez-Fuentes J, Duran-Lobato M, Prados J, Melguizo C, Fernandez-Arvelo M, Holgado MA. 2012. Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies. Int J Nanomed. 7:5793–5806.
   PubMed Web of Science ®Google Scholar
• Menon JU, Kona S, Wadajkar AS, Desai F, Vadla A, Nguyen KT. 2012. Effects of surfactants on the properties of PLGA nanoparticles. J Biomed Mater Res A. 100(8):1998–2005.
   PubMed Web of Science ®Google Scholar
• Mittal G, Sahana DK, Bhardwaj V, Kumar MNVR. 2007. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release. 119(1):77–85.
   PubMed Web of Science ®Google Scholar
• Miyoshi Y, Uemura H, Kubota Y. 2005. Treatment of androgen-independent hormone refractory prostate cancer using docetaxel. Nihon Rinsho. 63(2):298–302.
   PubMedGoogle Scholar
• Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65(1-2):55–63.
   PubMed Web of Science ®Google Scholar
• Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R, Puglisi G. 2006. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. 325(1-2):172–179.
   PubMedGoogle Scholar
• Mylonaki I, Allémann E, Delie F, Jordan O. 2018. Imaging the porous structure in the core of degrading PLGA microparticles: the effect of molecular weight. J Control Release. 286:231–239.
   PubMed Web of Science ®Google Scholar
• Öztürk AA, Yenilmez E, Şenel B, Kıyan HT, Güven UM. 2020. Effect of different molecular weight PLGA on flurbiprofen nanoparticles: formulation, characterization, cytotoxicity, and in vivo anti-inflammatory effect by using HET-CAM assay. Drug Dev Ind Pharm. 46(4):682–695.
   PubMed Web of Science ®Google Scholar
• Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM, Fahmy TM. 2009. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine. 5(4):410–418.
   PubMed Web of Science ®Google Scholar
• Prabaharan M, Grailer JJ, Pilla S, Steeber DA, Gong SQ. 2009. Folate conjugated amphiphilic hyperbranched block copolymers based on Boltorn H40, poly(L-lactide) and poly(ethylene glycol) for tumor-targeted drug delivery. Biomaterials. 30(16):3009–3019.
   PubMed Web of Science ®Google Scholar
• Rafiei P, Haddadi A. 2017. Docetaxel-loaded PLGA and PLGAPEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile. Int J Nanomed. 12:935–947.
   PubMed Web of Science ®Google Scholar
• Rafiei P, Haddadi A. 2019. A robust systematic design: optimization and preparation of polymeric nanoparticles of PLGA for docetaxel intravenous delivery. Mater Sci Eng C Mater Biol Appl. 104:109950.
   PubMed Web of Science ®Google Scholar
• Sanna V, Roggio AM, Posadino AM, Cossu A, Marceddu S, Mariani A, Alzari V, Uzzau S, Pintus G, Sechi M. 2011. Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies. Nanoscale Res Lett. 6(1):260.
   PubMedGoogle Scholar
• San Román B, Irache JM, Gómez S, Tsapis N, Gamazo C, Espuelas MS. 2008. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. Eur J Pharm Biopharm. 70(1):98–108.
   PubMed Web of Science ®Google Scholar
• Scholes PD, Coombes AG, Illum L, Davis SS, Watts JF, Ustariz C, Vert M, Davies MC. 1999. Detection and determination of surface levels of poloxamer and PVA surfactant on and the biodegradable nanospheres using SSIMS and XPS. J Control Release. 59(3):261–278.
   PubMed Web of Science ®Google Scholar
• Singh R, Lillard JW. 2009. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 86(3):215–223.
   PubMed Web of Science ®Google Scholar
• Sokol MB, Nikolskaya ED, Yabbarov NG, Zenin VA, Faustova MR, Belov AV, Zhunina OA, Mollaev MD, Zabolotsky AI, Tereshchenko OG, et al. 2019. Development of novel PLGA nanoparticles with co-encapsulation of docetaxel and abiraterone acetate for a highly efficient delivery into tumor cells. J Biomed Mater Res B Appl Biomater. 107(4):1150–1158.
   PubMed Web of Science ®Google Scholar
• Sun SW, Jeong YI, Jung SW, Kim SH. 2003. Characterization of FITC-albumin encapsulated poly(dl-lactide-co-glycolide) microspheres and its release characteristics. J Microencapsul. 20(4):479–488.
   PubMed Web of Science ®Google Scholar
• Vitorino C, Carvalho FA, Almeida AJ, Sousa JJ, Pais AACC. 2011. The size of solid lipid nanoparticles: an interpretation from experimental design. Colloids Surf B Biointerfaces. 84(1):117–130.
   PubMed Web of Science ®Google Scholar
• Wang B, Wang J, Shao J, Kouwer P, Bronkhorst EM, Jansen JA, Walboomers XF, Yang F. 2020. A tunable and injectable local drug delivery system for personalized periodontal application. J Control Release. 324:134–145.
   PubMed Web of Science ®Google Scholar
• Zewail MB, El-Gizawy SA, Osman MA, Haggag YA. 2021. Preparation and in vitro characterization of a novel self-nano emulsifying drug delivery system for a fixed dose combination of candesartan cilexetil and hydrochlorothiazide. J Drug Delivery Sci Technol. 61:102320.
   Web of Science ®Google Scholar